Citius Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that it has recently concluded negotiations to add South America to its worldwide license for Mino-Lok™.
South America was the only territory that was not included in the original sub-license between Novel Anti-Infective Technologies, LLC, an affiliate of MD Anderson Cancer Center (“MDACC”), and Leonard-Meron Biosciences, Inc. (“LMB”), a wholly owned subsidiary of Citius Pharmaceuticals, Inc.
Mr. Myron Holubiak, President and CEO stated, “The increasing importance of South American countries to the world market for pharmaceuticals and biotechnology made it compelling for us to include these countries in our license. Citius is committed to developing Mino-Lok as a cost saving therapy in all countries and will position Mino-Lok to find a receptive market for adoption everywhere.”
There are currently no approved therapies to salvage infected CVCs.
About Citius Pharmaceuticals, Inc. pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. We focus on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches. www.citiuspharma.com
Mino-Lok™ is under investigation and not approved for commercial use.
About MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 45 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospitals” survey. It has ranked as one of the nation’s top two hospitals since the survey began in 1990, and has ranked first for 11 of the past 14 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
Contact:
Andrew Scott
Vice President, Corporate Development
(O) 908-967-6676
ascott@citiuspharma.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/citius-pharma-announces-addition-of-south-america-to-world-license-300427951.html
SOURCE Citius Pharmaceuticals, Inc.
Released March 23, 2017
